Trial Profile

An Open, Multi-center, Single-arm Phase II Clinical Study to Evaluate the Efficacy and Safety of Recombinant Fully Human Anti-PD-1 Monoclonal Antibody (GLS-010 Injection) in Patients With Recurrent or Metastatic Cervical Cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 21 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

04 Dec 2023 Results (n=105) assessing safety and efficacy of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer published in the International Journal of Gynecological Cancer
06 Sep 2023 According to a Guangzhou Gloria Biosciences Media Release , data from this study was published in Annals of Oncology (2022) 33 (suppl_9): S1503-S1514. 10.1016/annonc/annonc1126.
06 Sep 2023 According to a Guangzhou Gloria Biosciences Media Release, data from this study was presented at the Society for Immunotherapy of Cancer (SITC), European Society for Medical Oncology (ESMO) IO and ESMO Asia in 2022 in poster and oral presentation sessions.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com